Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Episurf Medical to Launch Custom Ankle Implants Using Episealer® Technology

In what represents an innovative method to treat osteochondral lesions of the talus in the ankle, Stockholm, Sweden-based Episurf Medical is preparing to launch patient-specific Episealer® ankle implants.

This represents a new direction for the Episealer® technology, which Episurf developed to treat damaged knee cartilage with a patient-specific design based on medical imaging and 3D modeling. (Three Episealer knee devices are approved and commercialized in Europe, presently.)

The company seeks to perform the first ankle procedures in 2Q18.

In 2016, a surgeon implanted one patient in Germany with a custom-made Episurf device to treat an ankle joint lesion. The device was built to the surgeon’s specifications in a complex case for which a patient-specific implant was reported to be the only option. The procedure was deemed successful and the patient reported excellent results at 12-month follow-up.

Present approaches to treat osteochondral talus defects include arthroscopic debridement and bone marrow stimulation, autograft transfer, autogenous cancellous bone graft, ACI, metal resurfacing, etc.

Other industry-wide 1Q18 ankle-related headlines of note include: